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Background: Insulin is an effective treatment for achieving glycemic control and preventing 
complications in patients with diabetes. In order to make insulin therapy more acceptable to 
patients, newer formulations of insulin have been developed, such as biphasic insulins. Biphasic 
insulins conveniently provide both prandial and basal insulin in a single injection. One of the 
most well-studied biphasic insulins is biphasic insulin aspart 70/30.
Objective: Our goal was to review the current literature on the safety and efﬁ  cacy of biphasic 
insulin aspart in type 1 and type 2 diabetes.
Methods: A MEDLINE search was conducted using the terms “biphasic insulin aspart” to 
identify clinical studies and reviews.
Results: Biphasic insulin aspart more effectively reduces post-prandial glucose compared to 
other biphasic insulins and basal insulins. Compared to biphasic insulin aspart, fasting glucose 
levels are lower with NPH, similar with glargine, and similar or lower with biphasic human 
insulin. Treat-to-target trials have shown that a goal HbA1c below 6.5 or 7% can be achieved 
with biphasic insulin aspart. The risk of hypoglycemia is similar to or less than that seen with 
other biphasic insulins or NPH insulin.
Conclusion: Biphasic insulin aspart 70/30 is a safe and effective treatment option for patients 
with diabetes.
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Introduction
Diabetes currently affects more than 20 million people in the United States and 246 
million people worldwide (CDC 2005; International Diabetes Federation 2007). 
Unfortunately, the prevalence of this global healthcare epidemic is on the rise and it is 
projected to affect 366 million people in the world by 2030 (Wild 2004). Diabetes is a 
chronic disease that is associated with signiﬁ  cant morbidity and mortality, both of which 
contribute substantially to the healthcare costs of society (Johnson et al 2006; Nolan 
et al 2006). As a result, extensive research has been undertaken to identify effective 
interventions for reducing microvascular and macrovascular complications in patients 
with diabetes. Two landmark studies, the Diabetes Control and Complications Trial 
(DCCT) in type 1 diabetes and the UK Prospective Diabetes Study (UKPDS) in type 2 
diabetes, demonstrated that intensive glycemic control reduces the risk of microvas-
cular complications (UKPDS Group 1998; DCCT Group 2000). More recently, the 
Epidemiology of Diabetes Interventions and Complications (EDIC) trial, a follow-up 
to the DCCT, showed that intensive glycemic control also reduces the risk of mac-
rovascular complications in type 1 diabetes (Nathan et al 2005). As a result of these 
and other studies, the American Diabetes Association (ADA) currently recommends 
maintaining glycosylated hemoglobin (HbA1c)  7.0% to prevent microvascular and 
macrovascular complications (ADA 2007). The International Diabetes Federation 
(IDF) and the American College of Endocrinology (ACE) guidelines are even more Vascular Health and Risk Management 2007:3(6) 920
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stringent and recommend a goal HbA1c  6.5% (IDF Clinical 
Guidelines Task Force 2006; Lebovitz et al 2006).
In all patients with type 1 diabetes and in many with 
type 2 diabetes, insulin therapy is necessary for achieving 
these glycemic goals. Individuals with type 1 diabetes have 
an absolute deﬁ  ciency in insulin due to complete islet cell 
destruction (Daneman 2006). As a result, patients with type 1 
diabetes must take exogenous insulin to sustain life, prevent 
diabetic ketoacidosis, achieve glycemic control, and prevent 
serious long-term complications. In contrast, several different 
treatment options are available for achieving glycemic control 
in type 2 diabetes. These options include insulin, oral anti-
hyperglycemic agents, and newer injectables such as exenatide 
and pramlinitide (Sicat and Morgan 2007). Despite the presence 
of these multiple treatment modalities, insulin remains an 
important therapy for patients with type 2 diabetes. This is 
because the natural history of type 2 diabetes is characterized 
by progressive loss of beta cell function (Stumvoll et al 
2005). As a result, exogenous insulin therapy often becomes 
necessary to achieve adequate glycemic control, even in type 
2 diabetes (Tibaldi and Rakel 2007). Insulin therapy, when 
delivered appropriately, is almost always effective in achieving 
glycemic control in type 2 diabetes, even after other agents have 
failed (Mudaliar and Edelman 2001). Thus, insulin therapy is 
important in the treatment of both type 1 and type 2 diabetes.
Unfortunately, insulin therapy is currently being underuti-
lized in the most common type of diabetes, type 2 diabetes. 
More than half of patients with type 2 diabetes do not meet 
the current standards of glycemic control and many of these 
patients are not on insulin therapy (Koro et al 2004). To 
improve glycemic control in type 2 diabetes and prevent 
long-term complications, there has been increasing inertia in 
recent years to facilitate earlier initiation of insulin therapy 
in patients with uncontrolled type 2 diabetes (Blonde 2005). 
In an attempt to make insulin therapy more acceptable and 
practical for patients and their physicians, simpler, more 
convenient insulin formulations have been developed, such 
as biphasic (pre-mixed) insulin.
Currently available biphasic insulins include biphasic 
human insulins and the newer biphasic insulin analogs. 
Biphasic human insulins, such as biphasic human insulin 
70/30, have been in use for many years. Biphasic human 
insulins are mixtures of human neutral protamine Hagedorn 
(NPH) insulin and soluble human (Regular) insulin. The 
mealtime component of biphasic human insulins, soluble 
human insulin, has a delayed onset of action and prolonged 
duration. When soluble human insulin is administered sub-
cutaneously, alone or as a biphasic insulin in combination 
with NPH, it peaks in about 2–3 hours and remains in the 
circulation for up to 6 hours (Home et al 1999). Because of 
this delayed onset of action, biphasic human insulin can result 
in early post-prandial hyperglycemia followed by subsequent 
hypoglycemia. To minimize this risk, biphasic human insulin 
should be administered 30 minutes before a meal. As this 
is not very practical, biphasic human insulin is often inap-
propriately taken during or even after a meal.
In contrast, biphasic insulin analogs, such as biphasic 
insulin aspart 70/30 and biphasic insulin lispro 75/25, have 
more desirable pharmacological properties as they exhibit a 
more rapid onset of action and a shorter duration of action. 
Consequently, biphasic insulin analogs reduce post-prandial 
glucose (PPG) more effectively and are more physiologic 
than biphasic human insulins. Biphasic insulin analogs are 
also more convenient as they can be injected anytime within 
15 minutes before to immediately after a meal. The use of 
biphasic insulin analogs, particularly biphasic insulin aspart, 
both as monotherapy and as an adjunct to other therapies, has 
been the subject of interest in a number of recent trials and 
reviews (Halimi et al 2005; Rolla and Rakel 2005; Garber 
2006). This review will focus on the use of biphasic insulin 
aspart in the treatment of both type 1 and type 2 diabetes.
Methods
A MEDLINE search was conducted using the terms “bipha-
sic insulin aspart” to identify clinical studies and reviews of 
biphasic insulin aspart in humans published through March of 
2007. Twenty-ﬁ  ve original articles and 4 review articles that 
reported on the efﬁ  cacy or safety of biphasic insulin aspart 
in patients with type 1 or type 2 diabetes were reviewed. 
Additional relevant articles were obtained from the reference 
lists of these articles.
Biphasic insulin aspart
Biphasic insulin aspart 70/30 (NovoLog® Mix 70/30, Novo 
Nordisk, Bagsvaerd, Denmark) is the most well studied 
biphasic insulin analog, even more extensively studied than 
biphasic insulin lispro 75/25 (Humalog® Mix 75/25 , Eli 
Lily and Company, Indianapolis, Indiana). Biphasic insulin 
aspart 70/30, is an admixture consisting of 70% intermediate-
acting protamine-crystallized insulin aspart (not NPH) and 
30% rapid-acting non-protaminated (soluble) insulin aspart. 
Biphasic insulin aspart 70/30 has a single peak, which comes 
from its soluble component. Compared to biphasic human 
insulin 70/30 (NPH/Regular), biphasic insulin aspart 70/30 
has a more rapid and higher peak for more effective mealtime 
coverage (Figure 1) (Jacobsen et al 2000; Hermansen, Vascular Health and Risk Management 2007:3(6) 921
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Colombo et al 2002; McSorley et al 2002). When injected 
subcutaneously, protaminated insulin aspart crystals exhibit a 
delayed absorption pattern such that the duration of action of 
the intermediate component of biphasic insulin aspart is similar 
to human NPH insulin. The incorporation of protaminated 
insulin aspart in biphasic insulin aspart 70/30 conveniently 
eliminates the need for a separate basal insulin injection. When 
intermediate acting protamine-crystallized insulin aspart and 
rapid-acting non-protaminated insulin aspart are combined 
to form biphasic insulin aspart 70/30, the peak action of the 
biphasic insulin aspart occurs between one and four hours after 
injection with a total duration of action measured as long as 
24 hours (NovoLog Mix® 70/30 product label).
An additional advantage of biphasic insulin aspart therapy 
is that its physiologic time-action proﬁ  le makes it particularly 
effective in reducing postprandial hyperglycemia, which is 
being increasingly recognized as an important target in gly-
cemic management (Boehm et al 2004; Halimi et al 2005; 
ADA 2007). In patients with HbA1c  7.3%, a signiﬁ  cant 
proportion of overall glycemic control may be explained by 
elevations in PPG (Landgraf 2004). PPG remains elevated in 
many patients, even after fasting plasma glucoses have been 
lowered close to goal (Monnier et al 2003). Excursions in 
PPG have particular importance because they correlate more 
closely with progression of cardiovascular disease than either 
fasting glucose levels or HbA1c (Temelkova-Kurktschiev 
et al 2000; DECODE Study Group 2003). In addition, treat-
to-target studies have shown that more focused attention to 
PPG can slow the progression of atherosclerotic disease in 
diabetes (Leiter et al 2005).
Conventional basal-bolus therapy, consisting of three daily 
injections of rapid- or short-acting insulin at every meal and one 
or two additional basal insulin injections, target both PPG and 
fasting plasma glucose; however they are not always practical 
as they require multiple daily injections. Biphasic insulin 
therapy is more convenient than conventional basal-bolus 
therapy as it delivers basal-bolus insulin in fewer injections. A 
single injection of biphasic insulin aspart delivers both insulin 
coverage for a meal (prandial insulin) and more long-lasting 
insulin coverage (basal insulin), thus targeting PPG, while also 
maintaining control of fasting plasma glucose.
Another advantage of using biphasic insulin aspart is that it 
can be conveniently administered with an easy-to-use pen deliv-
ery device known as the FlexPen® (Novo Nordisk, Bagsvared, 
Denmark). Pen delivery systems are easier to use than insulin 
syringes and thus may improve adherence to insulin therapy 
(Korytkowski et al 2005). Compared to other pen delivery 
device systems, the FlexPen® is especially easy to use and well-
liked by patients. In a recent multicenter, open-label, crossover 
study, 133 patients with type 2 diabetes and HbA1c 8.5 ± 1.1% 
were randomized to twice-daily injections of biphasic insulin 
aspart 70/30 versus biphasic lispro insulin 75/25 via pen 
delivery systems. The ease of use and patient preferences for 
the biphasic insulin aspart pen (Novolog Mix 70/30 Flexpen®) 
versus the biphasic insulin lispro pen (Humalog Mix 75/25 
Humalog Pen®) were assessed. Despite comparable HbA1c 
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Figure 1 Mean postprandial insulin proﬁ  les in patients with type 2 diabetes after injection of biphasic insulin aspart 70/30 (z), biphasic insulin lispro 75/25 (∆), and biphasic 
human insulin 70/30 (). Reprinted with permission from Hermansen K, Colombo M, Storgarrd H, et al. 2002. Improved postprandial glycemic control with biphasic insulin aspart 
relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care, 25:883–8. Copyright © 2002 American Diabetes Association.Vascular Health and Risk Management 2007:3(6) 922
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levels and safety proﬁ  les, patients preferred the biphasic insulin 
aspart pen and experienced fewer problems with it than with the 
biphasic insulin lispro pen. The majority (74.6%) of patients 
preferred the convenience of the biphasic insulin aspart pen 
whereas only 14.3% preferred the biphasic insulin lispro pen 
(Niskanen et al 2004). In another randomized, crossover study 
involving 23 adult patients with type 1 diabetes, described in 
detail below, even though pen delivery devices were used to 
deliver both treatment regimens, 19 (83%) of patients preferred 
continuing with thrice-daily injections of biphasic insulin aspart 
with the option of additional bedtime NPH, whereas only 4 
patients chose to continue on regular insulin three times a day 
plus bedtime NPH (Chen, et al 2006).
Biphasic insulin aspart in type 2 
diabetes
In patients with type 2 diabetes, several studies have shown that 
biphasic insulin aspart 70/30 twice daily at breakfast and dinner 
is more effective in controlling PPG than other insulin regimens. 
In a systematic review of 21 published clinical trials comparing 
the efﬁ  cacy of biphasic insulin aspart 70/30 with other treatment 
strategies in patients with type 2 diabetes, Halimi et al found 
that biphasic insulin aspart 70/30 twice daily reduced PPG to 
a greater extent than biphasic human insulin 70/30 twice daily, 
NPH twice daily, or insulin glargine once daily. Fasting plasma 
glucose levels with biphasic insulin aspart were greater than 
with NPH insulin, but not signiﬁ  cantly different from insulin 
glargine. As many of the reviewed studies were not treat-to 
target, reductions in HbA1c with biphasic insulin aspart were 
similar to that seen with other insulins. Treat-to-target trials 
have shown that glycemic targets, such as the American Dia-
betes Association (ADA) recommended goal HbA1c  7%, can 
be effectively achieved with intensiﬁ  cation of biphasic insulin 
aspart therapy. In fact, many patients with type 2 diabetes may 
be able to achieve glycemic targets with the simple addition of 
once daily biphasic insulin aspart 70/30. Finally, this review 
found that the risk of major hypoglycemia is not increased, and 
the risk of minor hypoglycemia is similar with biphasic insulin 
aspart compared to the other insulins (Halimi et al 2005). Other 
studies in patients with type 2 diabetes have compared biphasic 
insulin aspart 70/30 to biphasic insulin lispro 75/25, exenatide, 
and different oral anti-hyperglycemic agents. These studies are 
reviewed below.
Biphasic insulin aspart compared to biphasic 
human insulin in type 2 diabetes
In a small randomized, double-blind, crossover study of 13 
patients with type 2 diabetes and a mean baseline HbA1c of 
7.7%, overall PPG excursions were signiﬁ  cantly improved 
with twice daily biphasic insulin aspart 70/30 compared to 
twice daily biphasic human insulin 70/30. Both insulins were 
associated with 7 or fewer minor hypoglycemic events where 
patients experienced hypoglycemic symptoms but did not need 
assistance to relieve them. There were no major hypoglycemic 
events requiring the assistance of another person or injections 
of glucose or glucagon (McSorley et al 2002). This was not a 
treat-to-target study as its purpose was to compare the pharma-
cokinetics and pharmacodynamics of biphasic insulin aspart 
with biphasic human insulin. In another randomized crossover 
study of 31 patients with type 2 diabetes with a mean HbA1c of 
8.7 ± 1.3%, when biphasic insulin aspart 70/30 was injected at 
the start of a standardized test meal, post prandial glucose was 
signiﬁ  cantly less compared to biphasic human insulin 70/30 
injected 15 minutes before or at the start of the test meal. If 
however, the biphasic insulin aspart was injected 15 minutes 
after the start of a meal, the PPG proﬁ  le was comparable to 
biphasic human insulin (Kapitza et al 2004).
A larger, 24-week, randomized, multicenter trial of 428 
patients with type 2 diabetes conﬁ  rms that biphasic insulin 
aspart lowers PPG more effectively than biphasic human 
insulin. The mean increment in PPG after breakfast was 
signiﬁ  cantly lower with biphasic insulin aspart 70/30 imme-
diately before meals than with biphasic human insulin 70/30 
thirty minutes before meals (mean ± SEM, 73.8 ± 2.9 mg/dL 
versus 103.3 ± 5 mg/dL; p   0.0001) (Iwamoto 2003). How-
ever, there were no statistically signiﬁ  cant differences in the 
HbA1c between the two groups at the end of the 24 weeks 
(7.31 ± 0.04% versus 7.2 ± 0.06%, for biphasic insulin aspart 
and biphasic human insulin, respectively) and also at the end 
of 48 weeks (7.37 ± 0.04% versus 7.35 ± 0.07%). During 
the trial the fasting blood glucose decreased slightly in both 
groups, although by the end of the 24 weeks it was signiﬁ  -
cantly higher in the biphasic insulin aspart group compared to 
the biphasic human insulin group (160.2 ± 2.3 versus 145.3 ± 
3.9 mg/dL, p = 0.001), when adjusting for baseline values. 
Fifty-six percent of those in the biphasic insulin aspart group 
and 57% of those in the biphasic human insulin group had 
at least one episode of hypoglycemia. The biphasic insulin 
aspart group had a 30% lower risk of minor hypoglycemia 
compared to the biphasic human insulin group, however this 
was not statistically signiﬁ  cant (relative risk 0.69; 95% CI 
0.46–1.04). Major episodes of hypoglycemia requiring the 
assistance of another person were rare. It is important to note 
that this trial was designed as a noninferiority trial, not as a 
treat-to-target study. Therefore, it does not fully assess the 
HbA1c lowering efﬁ  cacy of biphasic insulin aspart.Vascular Health and Risk Management 2007:3(6) 923
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Biphasic insulin aspart compared to biphasic 
insulin lispro in type 2 diabetes
Only one study has compared the effectiveness of biphasic 
insulin aspart 70/30 and biphasic insulin lispro 75/25 
(75% protaminated lispro and 25% soluble lispro), another 
commercially available biphasic insulin analog. This was 
an open-label, three period crossover study in which 61 
insulin-treated patients with type 2 diabetes and HbA1c 
8.3 ± 1.1% received a single injection of biphasic insulin 
aspart 70/30, biphasic insulin lispro 75/25, and biphasic 
human insulin 70/30, before breakfast on each of 3 separate 
days (Hermansen, Colombo et al 2002). Signiﬁ  cantly fewer 
PPG excursions were observed after biphasic insulin aspart 
70/30 compared to after biphasic insulin lispro 75/25 and 
to after biphasic human insulin 70/30, which suggests 
that biphasic insulin aspart more effectively reduces 
PPG compared to other biphasic insulins (Figure 2). The 
mean baseline fasting serum glucose was comparable 
between the two groups (151.2–154.8 mg/dL). A total of 
53 hypoglycemic episodes were reported during the study 
days, including 23 episodes with biphasic insulin aspart, 11 
episodes with biphasic human insulin, and 19 episodes with 
biphasic insulin lispro. Most of these episodes were mild, 
based on symptoms only, not conﬁ  rmed with blood glucose 
measurement, and resolved spontaneously. There were a 
few severe hypoglycemic episodes requiring assistance 
from another person, including 2 episodes with biphasic 
insulin aspart, 2 episodes with biphasic human insulin, and 
5 episodes with biphasic insulin lispro.
Biphasic insulin aspart as an adjunct 
to oral anti-hyperglycemic drugs in type 2 
diabetes
Due to progressive loss of beta cell function in type 2 diabe-
tes, oral anti-hyperglycemic drugs (OHD) gradually lose their 
effectiveness over time, and supplementation with exogenous 
insulin often becomes necessary (Mudaliar and Edelman 
2001; Stumvoll et al 2005; Tibaldi and Rakel 2007). Biphasic 
insulin aspart has been shown to be an effective adjunctive 
therapy for patients with type 2 diabetes who are failing 
OHD. Several studies suggest that when HbA1c levels are 
elevated in type 2 diabetics on OHD therapy, adding biphasic 
insulin aspart may more effectively improve glycemic control 
compared to adding another OHD.
A recent multinational, open-label, 16-week trial showed 
that when patients with type 2 diabetes are failing mono-
therapy with metformin, adding biphasic insulin aspart 
70/30 more effectively reduces HbA1c, compared to adding 
glibenclamide (glyburide) (Kvapil et al 2006). In this study, 
329 patients with type 2 diabetes who had elevated HbA1c 
(7.5%–13%) on metformin alone were randomized to receive 
biphasic insulin aspart 70/30 alone, biphasic insulin aspart 
70/30 plus metformin, or glibenclamide plus metformin. 
Biphasic insulin aspart was initiated at a total daily dose of 
0.2–0.3 units/kg of body weight. Half the total daily dose 
was given immediately before breakfast and the other half 
was given immediately before the evening meal. Insulin 
doses were titrated every 1–7 days in increments of 2–4 
units per injection to achieve a target blood glucose 90–144 
mg/dL. The breakfast dose was adjusted based on the post-
breakfast and pre-dinner blood glucose values and the dinner 
dose was adjusted based on the post-dinner, bedtime, and 
pre-breakfast blood glucose values. By the end of the trial, 
HbA1c levels had decreased by more than 1.5% in all three 
treatment groups. The combination biphasic insulin aspart 
plus metformin group had signiﬁ  cantly greater reductions in 
HbA1c compared to the biphasic insulin aspart monotherapy 
group (mean treatment difference 0.39 ± 0.15%, p = 0.007). 
Furthermore, in a subpopulation of 193 patients with HbA1c 
 9% at baseline, the HbA1c at the end of the trial was sig-
niﬁ  cantly lower in the biphasic insulin aspart plus metformin 
group compared to the glibenclamide plus metformin group 
(mean treatment difference, 0.46 ± 0.21%, p = 0.027). There 
was no difference in the mean prandial blood glucose incre-
ment (the average increment in blood glucose following 
breakfast, lunch, and dinner) between groups, however the 
glucose increment following lunch was signiﬁ  cantly lower 
in the glibenclamide plus metformin group compared to 
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insulin aspart 70/30 (BIAsp 30) compared to biphasic insulin lispro 75/25 (Mix 25), 
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the biphasic insulin aspart only group (−20.2 ± 5.9 mg/dL, 
p   0.001) and also compared to the biphasic insulin aspart 
plus metformin group (−12.6 ± 5.9 mg/dL, p = 0.036). The 
incidence of minor hypoglycemia deﬁ  ned as blood glucose 
 50 mg/dL with or without symptoms and not requiring the 
assistance of another person, was low and similar between 
treatment groups. In each treatment group, there were 
approximately 0.04 episodes per patient per week of minor 
hypoglycemia or hypoglycemia symptoms not conﬁ  rmed 
by blood glucose measurement. There were no major hypo-
glycemic episodes, deﬁ  ned as blood glucose  50 mg/dL, 
requiring assistance, and requiring food or IV glucose. Body 
weight increased in all three groups with a mean weight gain 
of 1.6 kg in the biphasic insulin apart only group, 0.8 kg in 
the biphasic insulin aspart plus metformin group, and 0.1 kg 
in the glibenclamide plus metformin group. In conclusion, 
this study showed that in patients with uncontrolled type 2 
diabetes on metformin alone, adding biphasic insulin aspart 
is more effective in reducing HbA1c than adding a sulfo-
nylurea, especially when the HbA1c is  9%. This is to be 
expected as higher HbA1c levels reﬂ  ect greater loss of beta 
cell function and decreased likelihood of responding to the 
addition of a sulfonylurea. This study also reassures us that 
biphasic insulin aspart can be added to metformin without 
inducing major hypoglycemia or increasing the risk of minor 
hypoglycemia or symptoms of hypoglycemia.
In an open-label, multicenter study, 246 patients with type 
2 diabetes who were failing OHD therapy with glibenclamide 
monotherapy or glibenclamide combination therapy with 
mean HbA1c 9.5% (range 7.4%–14.7%), were randomized 
to 18 weeks of biphasic insulin aspart 70/30 twice daily, 
biphasic insulin aspart 70/30 twice daily plus pioglitazone, 
or pioglitazone plus glibenclamide (Raz et al 2005). Com-
bination biphasic insulin aspart plus pioglitazone was more 
efﬁ  cacious in lowering HbA1c than combination gliben-
clamide plus pioglitazone (mean [SD] treatment difference, 
−0.64 % [0.23%]; p = 0.005) or even biphasic insulin aspart 
alone (mean (SD) treatment difference −0.60% [0.22%]; 
p = 0.008). The fasting blood glucose was signiﬁ  cantly lower 
in the biphasic insulin aspart plus pioglitazone group than in 
the glibenclamide plus pioglitazone group (mean ± SD, 153 
± 45 versus 169 ± 65 mg/dL; p = 0.012). The hypoglycemia 
event rate was low (fewer than 1 episode per patient-week 
in the biphasic insulin aspart only group) and there were 
no major hypoglycemic episodes. Edema was reported in 
 9% of patients in each treatment group, but there were no 
episodes of serious edema. Weight gain was more common 
in the biphasic insulin aspart plus pioglitazone group, where 
it affected 8% of patients. The mean weight gain was 4 kg 
and felt to be consistent with improved glycemic control. 
However, recent data suggest that patients on insulin may 
be at increased risk for cardiac complications related to 
rosiglitazone use. Therefore, thiazolidinediones should be 
used with caution in combination with insulin.
Biphasic insulin aspart versus NPH 
or glargine in type 2 diabetes
When insulin therapy is initiated in patients with type 2 
diabetes who are failing OHD, a common practice is to add 
a once-daily bedtime dose of basal insulin, either NPH or 
the insulin analog glargine (Lantus®, Sanoﬁ  -Aventis Phar-
maceuticals, Paris, France) (RiddLe et al 2003). As basal 
insulins primarily target fasting plasma glucose and do not 
address postprandial hyperglycemia, several studies have 
investigated whether biphasic insulin aspart may be a more 
effective ﬁ  rst-line adjunct insulin therapy in insulin-naïve 
type 2 diabetic patients who are failing OHD therapy.
In 2005, the INITIATE (INITiation of Insulin to reach A1c 
TargEt) study group reported that initiating insulin therapy 
with twice daily biphasic insulin aspart 70/30 was more 
effective in achieving HbA1c targets compared to initiating 
insulin therapy with once daily glargine. They conducted a 
28 week open-label, randomized treat-to-target trial, includ-
ing 233 insulin-naïve patients with type 2 diabetes who were 
poorly controlled with HbA1c  8% on  1.000 mg/day of 
metformin alone or in combination with other OHDs. A total 
of 263 subjects enrolled into the four-week run-in period, dur-
ing which the metformin dose was optimized to 1500–2550 
mg/day and secretagogues and alpha-glucosidase inhibitors 
were discontinued. Subjects on pioglitazone remained on it 
and those on rosiglitazone were switched to pioglitazone. At 
the end of the 4 week run-in period, 30 of the subjects were 
removed from the study as they had at least one self-measured 
plasma glucose  70 mg/dL or had both fasting plasma glu-
cose (FPG) and presupper plasma glucose levels that were 
 140 mg/dL. The remaining 233 patients were randomly 
assigned to either 5 to 6 units of biphasic insulin aspart 70/30 
twice daily or 10–12 units of glargine at bedtime. Insulin 
doses were titrated weekly for the ﬁ  rst 12 weeks and then 
every 2 weeks to achieve target FPG and presupper plasma 
glucose of 80–110 mg/dL according to a prespeciﬁ  ed algorithm 
(Raskin et al 2005). At the end of the 28 weeks, the mean 
HbA1c was 6.9% in the biphasic insulin aspart group and 7.4% 
in the insulin glargine group (p   0.01). In addition, 66% of 
people in the biphasic insulin aspart group achieved a HbA1c 
 7%, compared to only 40% in the insulin glargine group Vascular Health and Risk Management 2007:3(6) 925
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(p   0.001). The mean HbA1c reduction was greater in the 
biphasic insulin aspart group compared to the glargine group 
(mean HbA1c reduction, −2.79 ± 0.11% vs −2.36 ± 0.11%; 
p   0.01) This effect was more pronounced in patients with 
baseline HbA1c  8.5% (mean HbA1c reduction, −3.13 ± 
1.63% vs –2.6 ± 1.5%; p   0.05). Mean FPG was similar in 
the two treatment groups at baseline (252 ± 67.4 versus 243 ± 
68.8 mg/dL in the biphasic insulin aspart and glargine groups, 
respectively; p   0.05), and also the end of the study (127 ± 
40.6 versus 117 ± 44.3 mg/dL; p   0.05). Fifty-seven percent 
of subjects in the glargine group achieved target FPG 80–110 
mg/dL, compared to only 36% in the biphasic insulin aspart 
group. Still, the change in FPG from baseline was similar 
in both groups (125 ± 72.9 versus 125 ± 74.4 mg/dL in the 
biphasic insulin aspart and glargine groups respectively). Mean 
prandial plasma glucose increments (postprandial plasma glu-
cose – preprandial plasma glucose) were signiﬁ  cantly lower 
for breakfast and dinner in the biphasic insulin aspart group 
compared to the glargine group. Minor hypoglycemia, deﬁ  ned 
as blood glucose  56 mg/dL with or without symptoms, was 
greater in the biphasic insulin aspart group than in the glargine 
group (3.4 ± 6.6 versus 0.7 ± 2 episodes per year, p   0.05). 
Forty-three percent of subjects in the biphasic insulin aspart 
group reported minor hypoglycemia, compared to only 10% 
in the glargine group (p   0.05). However, there was only 
one episode of major hypoglycemia (deﬁ  ned as an episode 
with neurological symptoms of hypoglycemia that required 
assistance and had either a plasma glucose  56 mg/dL or 
reversal of symptoms after food, glucagon, or inravenous 
glucose). This episode of major hypoglycemia occurred in the 
glargine group. No subjects discontinued treatment because 
of hypoglycemia. Biphasic insulin aspart was also associated 
with more weight gain compared to insulin glargine (5.4 ± 
4.8 vs 3.5 ± 4.5 kg, p   0.01). The total daily insulin dose at 
the end of the study was greater in the biphasic insulin aspart 
group than in the glargine group (78.5 ± 39.5 versus 51.3 ± 
26.7 units/day).
In a subsequent report, baseline cohort characteristics 
and treatment effects from INITIATE were entered into the 
validated CORE diabetes model to simulate the range of 
diabetic complications and disease progression, and predict 
life expectancy, quality-adjusted life expectancy, cumula-
tive incidence of complications and direct medical costs 
over patient lifetimes (Valentine et al 2005). This modeling 
study found that reducing HbA1c levels with biphasic insulin 
aspart 70/30 was associated with improved life expectancy 
(0.19 ± 0.20 years) and quality-adjusted life expectancy 
(0.19 ± 0.14 quality-adjusted life years [QALYs]). Biphasic 
insulin aspart 70/30 was also projected to reduce the 
incidence of retinopathy and nephropathy complications 
compared to glargine.
More recently, the INITIATE data were entered into 
the validated Markov/Monte-Carlo simulation model and 
long-term treatment with biphasic insulin aspart 70/30 was 
projected to be cost-effective compared to glargine in patients 
with type 2 diabetes who fail OHD (Ray et al 2007). The 
incremental cost-effectiveness ratio was $46,533 per QALY 
gained with biphasic insulin aspart vs glargine. Biphasic 
insulin aspart was even more cost effective than glargine in 
patients with baseline HbA1c  8.5%, where the incremental 
cost-effectiveness ratio was only $34 916 per QALY gained 
with biphasic insulin aspart. The lifetime cost per patient 
treated successfully to target HbA1c levels of  7.0% and 
 6.5% were US$80,523 and US$93,242 lower with biphasic 
insulin aspart than with glargine, respectively.
A second, large, open-label study conﬁ  rms that initiating 
insulin therapy in type 2 diabetes with biphasic insulin aspart 
may reduce HbA1c and mean PPG increment to a greater 
extent than initiating insulin glargine. In this study 255 
insulin-naïve patients with type 2 diabetes were randomized 
to twice-daily biphasic insulin aspart 70/30 plus metformin 
versus once-daily insulin glargine plus glimepride (Kann 
et al 2006). The rationale for this study design was that basal 
insulin might be best used in combination with an insulin 
secretagouge. The mean HbA1c at baseline was 9.2 ± 1.5% 
in the biphasic insulin aspart plus metformin group and 8.9 ± 
1.3% in the glargine plus glimepride group (p = 0.07). At the 
end of 26 weeks, the mean change in HbA1c was statistically 
signiﬁ  cantly greater in the biphasic insulin aspart plus metfor-
min group compared to the insulin glargine plus glimepride 
group (between-group difference: −0.5% (95% CI = −0.8 
to −0.2%), p = 0.0002). In addition, the mean increment in 
PPG was signiﬁ  cantly lower in the biphasic insulin aspart 
plus metformin group than in the insulin glargine plus 
glimepride group (25.2 ± 25.2 versus 39.6 ± 32.4 mg/dL; 
p = 0.0002). Minor hypoglycemia occurred in 20% of sub-
jects in the biphasic insulin aspart plus metformin group and 
in 9% of subjects in the other group (p = 0.01). One major 
hypoglycemic episode occurred in each group. The mean 
change in weight was +1.5 kg (95% CI = 0.84 to 2.19 kg; 
p   0.0001) in the glargine plus glimepride group and +0.7 kg 
(95% CI = −0.07 to 1.42 kg; p = 0.08) in the biphasic insulin 
aspart plus metformin group.
Biphasic insulin aspart has also been compared to NPH 
insulin in insulin-naïve type 2 diabetic patients failing OHD. 
In an open-label 12-week study, 140 patients with type 2 Vascular Health and Risk Management 2007:3(6) 926
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diabetes who had HbA1c levels  7.5% on metformin alone 
or in combination with sulfonylurea were enrolled. All sub-
jects received metformin monotherapy for 4 weeks and then 
combination therapy with metformin and a once-a-day insulin 
for 12 weeks, either biphasic insulin aspart 70/30 once daily 
before dinner, biphasic human insulin 70/30 thirty minutes 
before dinner, or NPH insulin once daily at bedtime (Kilo 
et al 2003). The insulin dose was titrated during the ﬁ  rst 
four weeks to achieve a FPG between 90 and 126 mg/dL. 
After that, no further adjustments were made in the insulin 
dose. By the end of the 12 weeks, HbA1c had decreased by 
1.3%, 1.2%, and 1.1% in the bipasic insulin aspart, NPH, 
and biphasic human insulin groups, respectively. There were 
no statistically signiﬁ  cant differences in the 8-point blood 
glucose proﬁ  les, FPG, or HbA1c between the three treat-
ment groups. The largest reductions in HbA1c (−2.3% with 
biphasic insulin aspart, −1.9% with NPH, -1.8% with biphasic 
human insulin) were seen in those patients who achieved a 
ﬁ  nal FPG  126 mg/dL. Overall, FPG values decreased by 
31% with biphasic insulin aspart, by 37% with NPH insulin, 
and by 28% with biphasic human insulin. All three treat-
ment regimens were well tolerated. These results suggest 
that patients with type 2 diabetes can safely and effectively 
begin insulin therapy using once-daily injections of biphasic 
insulin aspart 70/30, biphasic human insulin 70/30, or NPH 
insulin in combination with metformin.
A recent large multinational randomized non-inferiority 
trial involving 394 patients with type 2 diabetes found that 
biphasic insulin aspart given three times a day with meals 
was as efﬁ  cacious as a basal-bolus insulin regimen consisting 
of three injections a day of soluble insulin aspart with meals 
plus a fourth daily injection of NPH at bedtime (Ligthelm 
et al 2006). Patients randomized to biphasic insulin aspart 
received biphasic insulin aspart 70/30 three times a day with 
meals if their BMI was  30 kg/m2. Those who were random-
ized to biphasic insulin aspart and had a BMI  30 kg/m2 
received biphasic insulin aspart 50/50 with breakfast and 
lunch and 70/30 with dinner. At the end of 16 weeks, the 
mean HbA1c decreased from 9.1 ± 0.7% to 7.8 ± 1% in both 
groups. Therefore, in patients with type 2 diabetes, biphasic 
insulin aspart three times a day with meals was not inferior 
to the more intensive 4-injections-per-day regimen of insu-
lin aspart with meals plus NPH at bedtime. In addition, the 
incidence of adverse events and hypoglycemia were similar 
in the two groups.
In one parallel, double-blind trial, 403 patients with 
uncontrolled type 2 diabetes on OHD and/or NPH insulin 
were randomized to receive biphasic insulin aspart 70/30 
twice a day or NPH twice a day for 16 weeks (Christiansen 
et al 2003). The mean baseline HbA1c was 8.8 ± 1.3% in 
the biphasic insulin aspart group and 8.8 ± 1.2% in the NPH 
group. OHDs were discontinued on randomization. The 
starting dose of insulin was 8 to 16 Units per day in insulin 
naïve patients at the discretion of the patient’s physician. 
The starting insulin doses in patients who had been on NPH 
insulin before the study were based on their previous insulin 
requirements. Both the NPH and the biphasic insulin aspart 
were administered immediately before breakfast and dinner. 
The target range for fasting/preprandial blood glucose was 
90 to 144 mg/dL. Insulin doses were titrated according to 
accepted treatment guidelines. HbA1c signiﬁ  cantly decreased 
from baseline in both groups, however there were no differ-
ences between groups. The mean reduction in HbA1c was 
0.67% in the biphasic insulin aspart group and 0.61% in the 
NPH group. Reductions in fasting blood glucose were similar 
in the two groups ( 25.2 versus 27 mg/dL in the biphasic 
insulin aspart and NPH groups, respectively), however the 
ﬁ  nal fasting blood glucose values were 17.1 mg/dL higher 
in the biphasic insulin aspart group (p   0.0001). The mean 
postprandial glucose increment was signiﬁ  cantly lower in the 
biphasic insulin aspart group compared to the NPH group. 
Thus, in patients with type 2 diabetes, biphasic insulin aspart 
twice daily was as effective in reducing HbA1c and more 
effective in reducing PPG compared to NPH twice daily. 
There were no differences in rates of hypoglycemia between 
the two groups with 33% of subjects in each group report-
ing minor hypoglycemia episodes, deﬁ  ned as hypoglycemic 
symptoms with or without conﬁ  rmation with blood glucose 
measurement that do not require the assistance of another 
person. There were 341 minor hypoglycemic episodes in 77 
patients in the biphasic insulin aspart group and 285 minor 
hypoglycemic episodes in 68 patients in the NPH group, 
but the relative risk between treatments was not signiﬁ  cant 
(RR = 1.21 and 95% CI 0.77–1.9; p = 0.4). Approximately 
11% of patients in each group experienced one or more 
minor nocturnal hypoglycemic episodes. Fewer than 2% 
of subjects in each group experienced major hypoglycemia 
episodes, deﬁ  ned as an episode requiring the assistance of 
another person or an injection of glucose or glucagon. In 
both groups, hypoglycemic episodes were noted to be more 
frequent during the ﬁ  rst week of treatment, but then they 
decreased in frequency with continued treatment.
In a multicenter open-label observational trial, 41 type 2 
diabetics with HbA1c levels above target despite treatment 
with OHD, alone or in combination with once daily basal 
insulin NPH or glargine, were switched to a forced titration Vascular Health and Risk Management 2007:3(6) 927
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algorithm using biphasic insulin aspart 70/30 once daily 
before supper (Jain et al 2004). In this algorithm, the biphasic 
insulin aspart dose was regularly adjusted to maintain fasting 
plasma glucose between 80 and 110 mg/dL. After 16 weeks 
on this treat-to-target algorithm, 39% of the patients (16 out 
of 41) achieved a HbA1c  7% and 22% of the patients 
(9 out of 41) achieved a HbA1c  6.5%.
Together these studies support the use of biphasic insulin 
aspart as a viable and efﬁ  cacious insulin therapy for patients 
with type 2 diabetes who are failing OHD. Initiating once-
daily injections of biphasic insulin aspart 70/30 at dinner 
appears to be as effective in lowering HbA1c as initiating 
once-daily injections of biphasic human insulin 70/30 at 
dinner or NPH insulin at bedtime. Initiating twice daily 
injections of biphasic insulin aspart is more effective in 
achieving HbA1c targets than initiating insulin glargine once 
daily. Compared to NPH twice daily, biphasic insulin aspart 
twice daily is as effective in reducing HbA1c and more effec-
tive in reducing PPG. Finally, biphasic insulin aspart three 
times a day with meals is as efﬁ  cacious in lowering HbA1c 
levels in patients failing OHD as a basal-bolus insulin regi-
men consisting of three injections a day of soluble insulin 
aspart with meals plus a fourth daily injection of NPH at 
bedtime. Overall, biphasic insulin aspart is more efﬁ  cacious 
than insulin glargine and as efﬁ  cacious as NPH or biphasic 
human insulin in lowering HbA1c levels in patients failing 
OHD. Biphasic insulin aspart reduces PPG excursions, and 
is effective in achieving HbA1c goals. Furthermore, biphasic 
insulin aspart is convenient, cost effective and well tolerated 
in patients with type 2 diabetes.
Biphasic insulin aspart compared 
to exenatide
Patients failing OHD have the option of initiating exenatide, 
a glucagon like peptide-1 (GLP-1) analog that increases 
glucose dependent insulin secretion, suppresses glucagon 
secretion, slows gastric emptying, and decreases food intake. 
Exenatide reduces HbA1c by only about 1%, but its main 
advantage is that it promotes weight loss. Thus many patients 
failing OHD are started on exenatide rather than insulin. 
In a recently published non-inferiority trial, 501 patients 
with type 2 diabetes who were failing OHD therapy with 
metformin and a sulfonylurea (baseline mean HbA1c 8.6% 
and Fasting serum glucose 198 mg/dL) were randomized to 
receive either twice-daily injections of exenatide or twice-
daily injections of biphasic insulin aspart 70/30 (Nauck et al 
2007). The starting dose of insulin for each patient was chosen 
by the investigator following randomization. Investigators 
were instructed to adjust insulin doses to optimize glycemic 
control, while avoiding signiﬁ  cant hypoglycemia. Patients 
were contacted at regular intervals to discuss their glycemic 
control, but no forced titration schedule was used in this study. 
Options available to help guide investigators in intensiﬁ  ca-
tion of insulin therapy include a titration guideline indicat-
ing minimal targets of  126 mg/dL for fasting glucose and 
 180 mg/dL for 2 hour postprandial glucose. Ultimately, 
the decision of whether or not to adjust insulin was left up to 
each investigator’s clinical judgment. On entry into the study, 
prior metformin and sulfonylurea doses were continued. If 
hypoglycemia occurred, the sulfonylurea dose was reduced 
by 50% in the exanetide group and the insulin dose was reas-
sessed in the biphasic insulin aspart group. Mean reduction in 
HbA1c was similar in the two groups (mean ± SEM change 
in HbA1c, −1.04 ± 0.07% with exenatide, and −0.89 ± 0.06% 
with biphasic insulin aspart) suggesting noninferiority of 
exenatide compared to biphasic insulin aspart, with respect 
to change in HbA1c. The mean change in fasting serum glu-
cose from baseline to week 52 was 32.4 ± 3.6 mg/dL in the 
exenatide group and 30.6 ± 3.6 mg/dL in the biphasic insulin 
aspart group. The difference between the two groups in mean 
change in HbA1c (exenatide-insulin) was −1.8 mg/dL (95% 
CI −10.8 to 7.2 mg/dL; p = 0.69). Greater reductions in PPG 
were reported with exenatide (morning meal p   0.001, mid-
day meal p = 0.002, and evening meal p   0.001). However, 
these results should be interpreted with some skepticism as 
80% of patients in the exenatide group were maximized on 
exenatide (10 μg a day), whereas there was no algorithm for 
titrating the insulin aspart. The mean total daily dose of bipha-
sic insulin aspart at 52 weeks was only 24 units, suggesting 
that the biphasic insulin aspart group may have been under 
treated. Furthermore, the mean HbA1c at baseline was only 
8.6% in this study. It is unlikely that exenatide would be as 
effective as insulin in achieving glycemic goals in patients 
with a higher HbA1c as reduction in HbA1c with exenatide 
is only about 1%.
A steady decline in the mean body weight was noted in 
the exenatide group throughout the study, while the biphasic 
insulin group gained weight. By the end of the 52 weeks the 
difference in mean change in body weight between groups 
was −5.5 ± 0.2 kg (95% CI −5.9 to −5 kg; p   0.001). There 
were statistically signiﬁ  cant reductions in the mean systolic 
blood pressure (−5 ± 15 mmHg, p   0.001) and the mean 
diastolic blood pressure (−2 ± 10 mmHg, p = 0.03) in the 
exenatide group. There were no signiﬁ  cant changes in blood 
pressure in the biphasic insulin group. Exenatide was associ-
ated with a higher incidence of gastrointestinal adverse events Vascular Health and Risk Management 2007:3(6) 928
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than biphasic insulin aspart. Hypoglycemia rates were similar 
in the two treatment groups (4.7 ± 0.7 events per patient-year 
in the exenatide group versus 5.6 ± 0.7 events per patient-
year in the biphasic insulin group). There were no episodes 
of severe hypoglycemia.
Biphasic insulin aspart in type 1 
diabetes
The evidence regarding biphasic insulin aspart therapy is 
sparser in the literature for type 1 diabetes than for type 2 
diabetes. This is probably partially due to the higher preva-
lence of the latter. In a randomized, crossover study involv-
ing 23 adult patients with type 1 diabetes and mean baseline 
HbA1c 9.2% (range 8.1%–12.3%), biphasic insulin aspart 
70/30 three times a day with bedtime NPH if necessary for 
12 weeks was superior to a more traditional basal-bolus 
insulin regimen consisting of soluble human insulin (regular 
insulin) three times a day and bedtime NPH for 12 weeks 
[mean and range HbA1c, 8.3% (6.7%–9.8%) after biphasic 
insulin aspart vs 8.6% (7.4%–11.4%) after regular insulin, 
p = 0.013] (Chen et al 2006). Biphasic insulin aspart was 
injected immediately before meals. Regular insulin was 
injected as it had been prior to trial entry and varied any-
where from 0 to 30 minutes before meals. When patients 
were randomized to the biphasic insulin aspart phase, the 
initial dose was based on their average daily dose the week 
before, 30% was given with breakfast, 30% with lunch, and 
40% with dinner. In addition, during this phase patients were 
advised by a diabetes nurse to take bedtime NPH if needed 
to control fasting hyperglycemia. Eleven of the 23 subjects 
chose to take bedtime NPH (2–10 units) during the biphasic 
insulin aspart phase. Those assigned to the regular insulin 
phase were started on the same doses that they had been on 
pretrial. Patients adjusted their insulin doses according to 
their self-monitored blood glucose and with advice from a 
diabetes nurse. Patients were given targets of 90–144 mg/
dL for preprandial blood glucose and 90 to 180 mg/dL for 
postprandial blood glucose. Although the percent of basal 
insulin was greater during biphasic insulin aspart treat-
ment, the total daily insulin doses during the two treatment 
phases were identical, averaging 50 units daily during both 
treatment phases. HbA1c signiﬁ  cantly improved with both 
treatments, but the improvement was signiﬁ  cantly greater 
with biphasic insulin aspart than with regular insulin, espe-
cially in those 11 patients who took bedtime NPH while 
in the biphasic insulin aspart phase. These 11 patients had 
a mean HbA1c of 8.7% (7.4%–11.4%) following regular 
insulin compared to a mean HbA1c of 8.2% (6.7%–9.8%) 
following biphasic insulin aspart (p   0.05). Analysis of 
self monitored blood glucoses revealed signiﬁ  cantly lower 
blood glucoses 2 hours after dinner and at bedtime during 
the biphasic insulin aspart phase compared to the regular 
insulin treatment phase. The mean (range) blood glucose 2 
hours after dinner was 173 (120–324) mg/dL with regular 
insulin versus 149 (90–220) mg/dL with biphasic insulin 
aspart. The mean blood glucose at bedtime was 176 (112–
283) mg/dL with regular insulin versus 148 (104–227) mg/
dL with biphasic insulin aspart. There were no signiﬁ  cant 
differences between the two treatments in the mean fasting 
blood glucose [153 (101–225) mg/dL with regular insulin 
versus 155 (112–227) mg/dL with biphasic insulin aspart]. 
There were no differences between the two treatments in 
blood glucoses 2 hours after breakfast, before lunch, 2 hours 
after lunch, or before dinner. The rate of total hypoglyce-
mic events, deﬁ  ned as either symptoms of hypoglycemia 
and/or blood glucose  50 mg/dL, was not signiﬁ  cantly 
different between treatments [median (range), 0.7 (0–3.3) 
versus 1.2 (0.1–3.1) events per patient per week with the 
regular insulin and biphasic insulin aspart, respectively]. 
During biphasic insulin aspart treatment, the rate of total 
hypoglycemic events was 1.1 (0.3–1.9) events per patient 
per week in the 12 patients who did not take bedtime NPH 
compared to 1.2 (0.1–3.1) events per patient per week in 
the 11 patients who also took bedtime NPH. The rate of 
nocturnal hypoglycemia occurring between midnight and 
4 am was the same during the two treatments, 0.2 (0.1–0.7) 
events per patient per week. There was one episode of 
major hypoglycemia during regular insulin treatment and 
3 episodes in 2 patients during biphasic insulin aspart treat-
ment. Major hypoglycemia was deﬁ  ned as symptomatic 
hypoglycemia requiring the assistance of another person. 
(Chen et al 2006).
In another large study, 104 adult patients with type 1 
diabetes and 187 adult patients with type 2 diabetes who 
were on twice-daily insulin injections with a mean baseline 
HbA1c of 8% were randomized to twice daily biphasic 
human insulin 70/30 or biphasic insulin aspart 70/30. After 
12 weeks, the mean daily PPG increment was signiﬁ  cantly 
lower with biphasic insulin aspart compared to biphasic 
human insulin (difference between groups −12.2 mg/dL 
(90% CI −2.9 to −21.6 mg/dL; p   0.02). (Boehm et al 
2002). Blood glucoses after breakfast, before lunch, after 
dinner and at bedtime were about 18 mg/dL lower in the 
biphasic insulin aspart group compared to the biphasic 
human insulin group (p   0.05). Fasting blood glucose 
was not statistically signiﬁ  cantly different between the Vascular Health and Risk Management 2007:3(6) 929
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two treatment groups (161 ± 5.0 mg/dL in the biphasic 
insulin aspart group versus 148 ± 4.9 mg/dL in the biphasic 
human insulin group. The mean difference in fasting blood 
glucose between the treatment groups (biphasic insulin 
aspart – biphasic human insulin) is 12 mg/dL (95% CI −0.9 
to 25 mg/dL). There was also no signiﬁ  cant differences in 
mean HbA1c between the two treatments (mean ± SEM, 
8.14 ± 0.06% versus 8.15 ± 0.06%). The number of major 
hypoglycemic episodes, defined as requiring another 
person’s assistance or IV glucose or glucagon, was twice 
as great with biphasic human insulin compared to biphasic 
insulin aspart (42 versus 20 major episodes), however this 
did not achieve statistical signiﬁ  cance, partly because 19 of 
the 42 episodes in the biphasic human insulin group occurred 
in only 3 patients. There were 361 minor hypoglycemic epi-
sodes with biphasic human insulin and 362 minor episodes 
with biphasic insulin aspart. Signiﬁ  cant risk factors for major 
hypoglycemia were type 1 diabetes and longer duration of 
diabetes. Minor hypoglycemia was deﬁ  ned as symptoms 
of hypoglycemia, conﬁ  rmed by a blood glucose reading if 
possible, and not requiring the assistance of another person. 
The overall risk of major and minor hypoglycemia was not 
signiﬁ  cantly different between the two treatment groups. 
Thus, compared to biphasic human insulin, biphasic insulin 
aspart twice daily signiﬁ  cantly improved PPG control in 
patients with type 1 and type 2 diabetes. Overall glucose 
control or HbA1c and overall risk of hypoglycemia was 
similar in the two treatment groups. Subsequently, 125 of 
the patients with type 2 diabetes participated in a 2-year 
extension of this trial (Boehm et al 2004). After 2 years, 
mean HbA1c was not statistically different between the two 
treatment groups (8.35 ± 0.20% in the biphasic insulin aspart 
group vs 8.13 ± 0.16% in the biphasic human insulin group; 
adjusted mean difference 0.03% (90% CI −0.29 to 0.34%), 
p = 0.89) However, as this was not a treat-to-target study, 
it does not address the efﬁ  cacy of biphasic human insulin 
aspart for achieving target HbA1c levels. The proportion 
of patients who experienced a major hypoglycemia episode 
was similar in both treatment groups during the ﬁ  rst year 
(5% with biphasic insulin aspart and 8% with biphasic 
human insulin, p = 0.72), but was signiﬁ  cantly lower in 
the biphasic insulin aspart group during the second year 
(0% with biphasic insulin aspart versus 10% with biphasic 
human insulin, p = 0.04). There was no signiﬁ  cant differ-
ence between the two treatment groups in the proportion of 
patients experiencing minor hypoglycemia. The change in 
body weight was 0.05 ± 0.81 kg in the biphasic insulin aspart 
group and 2 ± 0.69 kg in the biphasic human insulin group 
(p = 0.07). Thus, in patients with type 2 diabetes, biphasic 
insulin aspart was associated with a reduced rate of major 
hypoglycemia, despite a similar HbA1c, after 24 months.
A multinational, randomized, open-label, parallel group 
trial compared biphasic insulin aspart to bipasic human 
insulin in patients with type 1 diabetes (Mortensen et al 
2006). In this study, 167 adolescents, 10–17 years of age, 
with type 1 diabetes and mean baseline HbA1c of 9.6% were 
randomized to biphasic insulin aspart 70/30 three times a 
day before meals or biphasic human insulin 70/30 before 
breakfast and regular insulin before lunch and dinner. The 
starting total daily dose of insulin was the same as the total 
daily insulin dose at screening. If judged necessary by the 
investigator, additional doses of insulin aspart or regular 
insulin could be given before snacks or NPH could be given 
at bedtime. The glycemic goals in this study include fasting 
blood glucose  144 mg/dL and postprandial blood glucose 
 180 mg/dL. Dose adjustments were made based on these 
goals, HbA1c, and frequency of hypoglycemia. At the end 
of 16 weeks, there were small reductions in HbA1c in both 
groups. However, the end-of-study HbA1c was similar in the 
two treatment groups (9.39 ± 0.14% with biphasic insulin 
aspart versus 9.3 ± 0.15% with human insulin, p = 0.62 
after adjusting for baseline HbA1c and country). The mean 
PPG increment in the human insulin group was twice that 
in the biphasic insulin aspart group (6.7 ± 7.4 mg/dL versus 
13.9 ± 7.9 mg/dL); however, this did not achieve statistical 
significance (p = 0.47). Overall, the body mass index 
(BMI) increased in both groups but signiﬁ  cantly less so 
with biphasic insulin aspart (0.16 ± 0.1 versus 0.56 ± 0.11, 
p = 0.005). Interestingly, male subjects treated with biphasic 
insulin aspart had a reduction in their BMI of −0.13 ± 0.16, 
whereas male patients treated with human insulin had an 
increase in BMI of 0.41 ± 0.18 (p = 0.007). Females treated 
with biphasic insulin had a mean increase in BMI of 0.21 ± 
0.14 compared to females treated with human insulin who 
had a mean increase in BMI of 0.43 ± 0.16; however, this 
was not statistically signiﬁ  cant (p = 0.276). The incidence of 
major and minor hypoglycemic events was comparable in the 
two treatment groups. There were 15 major hypoglycemic 
episodes, 7 in the biphasic insulin aspart group and 8 in the 
human insulin group. The relative risk of experiencing a 
major episode was not signiﬁ  cantly different in the treatment 
groups. Most subjects experienced only a few episodes, but 
a few subjects had a high number of episodes. Ten subjects 
were responsible for reporting more than 600 (or 30% of) 
episodes. Six patients in the biphasic insulin aspart group 
reported 382 episodes and 4 people in the human insulin Vascular Health and Risk Management 2007:3(6) 930
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group reported 221 episodes. The majority of reported 
hypoglycemia episodes were symptoms only, and not 
conﬁ  rmed by blood glucose measurement.
In summary, several studies suggest that biphasic insulin 
aspart 70/30 may be a safe and effective alternative for some 
patients with type 1 diabetes. Compared to a basal-bolus 
regimen of regular insulin three times a day before meals 
plus NPH at bedtime, biphasic insulin aspart three times a 
day before meals ± bedtime NPH more effectively reduces 
HbA1c while maintaining similar rates of hypoglycemia. 
Another study involving both type 1 and type 2 diabetics 
showed that biphasic insulin aspart twice daily signiﬁ  cantly 
improves PPG control while achieving similar HbA1c levels 
compared to biphasic human insulin twice daily. The over-
all risk of hypoglycemia was similar in the two treatment 
groups, however having type 1 diabetes was a risk factor 
for major hypoglycemia. In adolescents 10–17 years old, 
biphasic insulin aspart before breakfast, lunch and dinner 
is as effective in lowering HbA1c as a regimen of biphasic 
human insulin before breakfast plus regular insulin before 
lunch and dinner. Interestingly males treated with biphasic 
insulin aspart had a slight reduction in BMI, whereas BMI 
increased in males treated with biphasic human insulin and 
females treated with biphasic human insulin or biphasic insu-
lin aspart. The incidence of major and minor hypoglycemia 
was comparable in the two treatment groups. Most subjects 
experienced only a few episodes, but a few subjects were 
particularly susceptible to hypoglycemia and reported a high 
number of episodes.
Biphasic insulin aspart 
and hyperlipidemia
In the previously described study by Kvapil et al involving 
341 patients with type 2 diabetes, triglyceride levels decreased 
by 44–53 mg/dL in the two biphasic insulin aspart groups and 
by only 18 mg/dL in the glibenclamide plus metformin group. 
However, there were no statistically signiﬁ  cant differences 
between the treatment groups in the mean triglyceride level 
at the end of the 16 weeks (176 ± 106 mg/dL with biphasic 
insulin aspart versus 202 ± 132 mg/dL with biphasic 
insulin aspart plus metformin versus 176 ± 97 mg/dL with 
glibenclamide plus metformin). HDL cholesterol increased 
slightly by 4–8 mg/dL in all three treatment groups, but this 
did not meet statistical signiﬁ  cance (Kvapil et al 2006). In the 
1-2-3 study of 100 patients with type 2 diabetes, discussed in 
detail below, signiﬁ  cant improvements were seen in fasting 
lipids with biphasic insulin aspart 70/30, including a 20% 
decrease in triglycerides, 9% increase in HDL cholesterol, 
and 5% decrease in total cholesterol. There was no change 
in LDL cholesterol (Garber et al 2006).
Studies on the effects of biphasic insulin aspart versus 
biphasic human insulin on postprandial hyperlipidemia in 
patients with diabetes have been inconsistent. One small 
study of 12 patients with type 2 diabetes found a signiﬁ  cant 
reduction in postprandial hyperlipidemia with biphasic insu-
lin aspart compared to biphasic human insulin (maximum 
increase in triglycerides, 205 ± 90.4 mg/dL with biphasic 
human insulin vs 145 ± 60.6 mg/dL with biphasic insulin 
aspart, p = 0.014) (Schmoelzer et al 2005). A randomized 
crossover study of 50 patients with type 1 diabetes reported 
a reduction in postprandial glucose with biphasic insulin 
aspart 70/30 compared to biphasic human insulin 70/30, but 
there were no differences in the postprandial free fatty acid or 
triglyceride levels between the two treatments (Hermansen, 
Vaaler et al 2002).
Optimal dosing frequency 
of biphasic insulin aspart
The optimal dosing frequency of biphasic insulin aspart 
when used in combination with OHD in those that have 
failed OHD alone has been investigated. The results of the 
1-2-3 study suggest that in many patients with type 2 diabe-
tes, biphasic insulin aspart 70/30 may need to be titrated to 
three daily injections to achieve optimum glycemic control 
(Garber et al 2006). This was a 48-week observational 
study that enrolled 100 patients with type 2 diabetes with 
a HbA1c of 7.5%–10% on at least two OHDs or on one 
OHD plus once-daily basal insulin. The basal insulin was 
discontinued on entry into the study, while the OHDs were 
continued as previously. All subjects were initiated on once 
daily dinnertime biphasic insulin aspart 70/30 (12 units or 
70%–100% of prior basal insulin dose). Under the guid-
ance of the investigator, subjects self-titrated their biphasic 
insulin aspart dose every 3–4 days to a target fasting blood 
glucose of 80–110 mg/dL. If a subject’s HbA1c was greater 
than 6.5% by week 15, oral insulin secretagogues were dis-
continued and a second injection of biphasic insulin aspart 
70/30 was initiated at a dose of 3–6 units with breakfast. 
Subjects adjusted their breakfast dose every 3–4 days to 
achieve pre-dinner blood glucose levels 80–110 mg/dL. 
They continued to adjust their dinner dose to achieve fast-
ing blood glucose levels 80–110 mg/dL. After another 
16 weeks, if a subject’s HbA1c was still greater than 6.5%, 
a third injection of biphasic insulin aspart was added at 
a dose of 3 units with lunch. This lunchtime dose was 
adjusted to achieve a PPG of 100–140 mg/dL 2 hours after Vascular Health and Risk Management 2007:3(6) 931
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lunch. Subjects were also allowed to continue to adjust their 
breakfast and dinner doses, but were cautioned not to adjust 
more than one dose at a time. The addition of once-daily 
biphasic insulin aspart at dinner allowed 21% of patients to 
achieve a HbA1c  6.5%, and 41% of patients to achieve 
a HbA1c  7.0%, in accordance with IDF and ADA guide-
lines. When patients were titrated to twice-daily biphasic 
insulin aspart, 52% achieved a HbA1c  6.5%, and 70% 
achieved a HbA1c  7.0%. Upwards titration to thrice daily 
dosing of biphasic insulin aspart allowed 60% of patients 
to achieve a HbA1c  6.5%, and 77% to achieve a HbA1c 
 7.0%. The mean HbA1c for all patients decreased from 
8.6 ± 0.8% at baseline to 6.6 ± 0.9% at the end of the study. 
Self monitored fasting blood glucose also decreased signiﬁ  -
cantly from a baseline of 175–180 mg/dL to 115–120 mg/dL 
after biphasic insulin treatment. The mean laboratory-mea-
sured fasting plasma glucose was 125 ± 59 mg/dL for at the 
end of the study. Most (84%) of patients reported minor 
hypoglycemia, deﬁ  ned as blood glucose  56 mg/dL, with 
or without symptoms, that the patient was able to treat them-
selves. The minor hypoglycemia rate was 15.4, 22.4, and 
12 events per patient year during once-daily, twice-daily, 
and thrice-daily dosing, respectively. Thus, increasing the 
number of daily injections does not appear to signiﬁ  cantly 
increase the risk for minor hypoglycemia. Interestingly, 
approximately half of all the minor hypoglycemia epi-
sodes were reported by only 13 patients. Perhaps in such 
patients who are particularly susceptible to hypoglycemia, 
a less aggressive titration schedule may have reduced the 
frequency of hypoglycemia. Major hypoglycemia, deﬁ  ned 
as blood glucose  56 mg/dL with CNS symptoms and 
requiring the assistance of another person, was reported by 
7 patients. The risk of major hypoglycemia was similar with 
the once-daily, twice-daily, and thrice-daily treatments. 
There were no nocturnal major hypoglycemic episodes. 
There were 33 patients who reported two or fewer minor 
or major hypoglycemia episodes. No patient withdrew from 
the study because of hypoglycemia. This trial demonstrated 
that biphasic insulin aspart 70/30 can be safely and effec-
tively titrated to achieve glycemic control in the majority 
of patients with uncontrolled type 2 diabetes.
In another randomized, open-label study of 177 patients 
with type 2 diabetes, biphasic insulin aspart with breakfast, 
lunch, and dinner signiﬁ  cantly improved post lunch and post 
dinner glucose proﬁ  les compared to biphasic insulin aspart 
twice daily (post lunch 156 vs 176 mg/dL, p = 0.0289 and 
post dinner 154 vs 182 mg/dL p = 0.002) (Abrahamian et al 
2005). The mean difference in HbA1c between treatment 
groups was 0.08% after 24 weeks, but this was not statisti-
cally signiﬁ  cant.
Safety proﬁ  le of biphasic insulin 
aspart
Hypoglycemia
The most common side effect of all insulin products is 
hypoglycemia, emphasizing the importance of self monitor-
ing blood glucose in all patients on insulin therapy. This is 
no surprise as hypoglycemia is the major limiting factor in 
achieving glycemic control in patients on insulin. Care should 
be taken when any kind of insulin is used in combination 
with beta blockers and clonidine as these drugs may mask 
symptoms of hypoglycemia (Provider 2006).
A systematic review of randomized comparative studies 
involving the use of biphasic insulin aspart 70/30 in type 2 
diabetes showed that the rates of minor hypoglycemia with 
biphasic insulin aspart 70/30 varied across studies, but was 
generally not different from the rates seen with biphasic 
human insulin 70/30, biphasic insulin lispro 75/25, or NPH 
insulin (Halimi et al 2005). The rates of severe hypoglycemic 
events with biphasic insulin aspart 70/30 were low. Com-
pared to biphasic human insulin 70/30, the rates of severe 
hypoglycemia with biphasic insulin aspart 70/30 were either 
similar or lower.
During the ﬁ  rst 12 months of the study by Boehm et al 
described in detail above, there was no signiﬁ  cant difference 
in the rate of major hypoglycemia between biphasic insulin 
aspart and biphasic human insulin (Boehm et al 2002). How-
ever, during the second year of the trial, major hypoglycemic 
events were signiﬁ  cantly reduced in the biphasic insulin 
aspart group compared to the biphasic human insulin group 
(Boehm et al 2004). In the second year of this study, using 
biphasic insulin aspart instead of biphasic human insulin 
reduced major nocturnal hypoglycemia by 38% and minor 
nocturnal hypoglycemia by 37%, despite similar HbA1c 
levels. One possible explanation for the reduced hypogly-
cemia seen with biphasic insulin aspart is that its mealtime 
component, rapid-acting insulin aspart, has a shorter duration 
of action (4 hours) compared to regular insulin (6 hours). 
Another explanation might be that patients on biphasic human 
insulin are more likely to inject their insulin inappropriately 
late as it is difﬁ  cult to time insulin injections 30 minutes 
before meals.
In a systematic review of 17 publications through February 
2005, including more than 2600 adults with type 2 diabetes 
[mean (range) baseline HbA1c 8.6% (7.5%–9.9%)] and 104 Vascular Health and Risk Management 2007:3(6) 932
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adults with type 1 diabetes (HbA1c 8.4% (7.2%–10.4%)), the 
overall incidence of hypoglycemia was comparable between 
biphasic insulin aspart 70/30, biphasic human insulin 70/30 
and biphasic insulin lispro 75/25 (Davidson et al 2005). In 
this report, hypoglycemic episodes occurred in 43%–57% 
of patients using biphasic insulin aspart, in 32%–57% of 
patients receiving biphasic human insulin, and in 28% of 
patients using basal NPH insulin. Major hypoglycemic events 
in which symptoms required assistance, glucagon, or IV glu-
cose were reported less often with the use of biphasic insulin 
aspart (2%–8%) than with the use of biphasic human insulin 
(2%–14%). This review also found no signiﬁ  cant differences 
in weight gain, formation of cross-reactive antibodies, or 
adverse events between biphasic insulin aspart and biphasic 
human insulin. Adverse events were reported in 36%–90% 
of patients on biphasic insulin aspart, 38%–88% of patients 
on biphasic human insulin, and 51% of patients on biphasic 
insulin lispro. Interestingly, the use of OHD was not found to 
signiﬁ  cantly alter the safety proﬁ  le of biphasic insulin aspart. 
Efﬁ  cacy parameters were not assessed in this review.
In another recent study of 157 insulin-naïve patients with 
type 2 diabetes and HbA1c  8%, subjects were randomized 
to biphasic insulin aspart 70/30 twice daily plus metformin 
or insulin glargine once daily plus metformin. In both groups 
insulin doses were titrated weekly according to a pre-speciﬁ  ed 
algorithm. Subjects in the biphasic insulin aspart group expe-
rienced more weight gain and minor hypoglycemic events 
than subjects in the insulin glargine group (Raskin et al 
2007). This may simply be a consequence of better glycemic 
control, as the proportion of subjects who achieved a HbA1c 
 7% at 28 weeks was greater in the biphasic insulin aspart 
group than in the insulin glargine group (65% versus 41%, 
p = 0.003). The mean change in HbA1c was −2.89 ± −1.6% 
with biphasic insulin aspart and −2.46 ± −1.6% with insulin 
glargine (p = 0.035). There were no major episodes of hypo-
glycemia, but nocturnal hypoglycemia was reported by 25% 
of the biphasic insulin aspart group compared to only 10% 
of the insulin glargine group (p = 0.021).
Weight gain
In the above study by Raskin et al weight gain was 5.6 ± 4.6 kg 
in the biphasic insulin aspart group and 3 ± 4.3 kg in the insulin 
glargine group (p = 0.0004) (Raskin et al 2007). The greater 
weight gain in the biphasic insulin aspart group may be due 
to the increase in minor hypoglycemia, as treatment of the 
hypoglycemia may lead to increased caloric consumption. The 
greater weight gain may also be a reﬂ  ection of better glycemic 
control as improved glycemic control itself is associated with 
weight gain and increased risk for hypoglycemia (Henderson 
et al 2003). Improved glycemic control can lead to weight gain 
as it reduces glucosuria so that calories are stored rather than 
lost in the urine. In a systemic review of 21 trials of biphasic 
insulin aspart in patients with type 2 diabetes, the amount of 
weight gain seen with biphasic insulin aspart varied from as 
little as 0.05 kg to as much as 5.4 kg, depending on the dura-
tion of treatment, degree of titration, and underlying patient 
population (Halimi et al 2005).
Insulin antibodies
As with other insulins, cross-reactive antibiodies have been 
reported to develop with the use of biphasic insulin aspart, 
however the clinical signiﬁ  cance of this is not known. In a 
study of 294 patients with either type 1 or type 2 diabetes, 
patients were randomized to treatment with either twice 
daily biphasic insulin apart or biphasic human insulin 70/30 
(Lindholm et al 2002). Patients were then tested for cross-
reactive insulin antibodies at 0, 3, 6, and 12 months. During 
treatment there was an initial 11.2% increase from baseline 
in cross reactive antibodies in patients receiving biphasic 
insulin aspart, followed by a decrease over the next several 
months. However, there was no correlation between cross 
reactive insulin antibodies and blood glucose control or 
adverse outcomes. Another 12-week study of multiple daily 
injections of biphasic insulin aspart in patients with type 1 
diabetes also found no differences in long-term glycemic 
control between patients with different levels of insulin 
antibodies (Chen et al 2005).
Other potential adverse events
Insulin aspart contains cresol, a compound that can cause 
local injection reactions and generalized myalgias. Cresol 
is also a component in insulin detemir, insulin glargine, and 
lispro (NovoLog Mix® 70/30 product label).
Advantages versus disadvantages 
of biphasic insulin aspart
As large epidemiologic studies suggest that PPG levels 
correlate better with adverse cardiovascular outcomes and 
death, one potential advantage of biphasic insulin aspart is 
better PPG control. Improvements in PPG control may also 
have the potential to reduce other diabetes complications, 
but this has yet to be proven in prospective, randomized 
controlled trials.
An important limitation of biphasic insulin aspart is that 
it is only available in certain proportions, most commonly 
70/30. This limitation, also seen with other biphasic insulins, Vascular Health and Risk Management 2007:3(6) 933
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may not be of particular signiﬁ  cance in patients with type 2 
diabetes who still maintain some endogenous insulin secre-
tion. Furthermore, using biphasic insulin eliminates the need 
for patients to mix their own insulin, which can be a potential 
source of error. Nevertheless, there will be patients who 
are unable to achieve glycemic goals with biphasic insulins 
because of its ﬁ  xed proportions and such patients may beneﬁ  t 
from learning how to mix NPH and a rapid-acting insulin, 
rather than using premixed biphasic insulins.
Another potential limitation of all biphasic insulins are 
that their basal components exhibit an intermediate NPH-like 
proﬁ  le rather than a more physiologic, truly basal insulin 
proﬁ  le as is seen with insulin glargine or levemir. NPH peaks 
several hours after it is injected, requiring patients on bipha-
sic insulins to eat at ﬁ  xed times of the day. Some patients 
may even need to have mid-morning and bedtime snacks to 
avoid hypoglycemia when the NPH insulin peaks. Therefore, 
some patients may prefer to switch to a more physiologic 
basal-bolus regimen of glargine or levemir once a day plus 
rapid-acting insulin three times a day. Glargine and levemir 
are peakless basal insulins that last 24 hours, however they 
cannot be mixed with other insulins.
Although basal-bolus insulin regimens are more physi-
ologic, they require four insulin injections daily and are more 
labor-intensive than biphasic insulin aspart 70/30 which may 
need to be given once, twice, or maybe thrice daily to achieve 
glycemic control. Thus for the less adherent patient, biphasic 
insulin aspart may be preferable to a basal bolus regimen.
Despite these limitations, the above studies show that 
many patients with type 2 diabetes and some patients with 
type 1 diabetes can achieve glycemic control safely and 
effectively with biphasic insulin aspart 70/30. Studies have 
also shown that the biphasic insulin aspart pen is particularly 
well-liked by patients because of its convenience and ease 
of use. Thus, in many patients the potential limitations of 
biphasic insulin aspart are likely outweighed by its ease of 
use, convenience, and greater acceptability.
On the other hand, for other patients, such as those who 
do not consume meals at ﬁ  xed times, the disadvantages of 
biphasic insulin aspart may outweigh its advantages, and 
alternative treatment regimens may be more appropriate. 
Thus, when deciding on whether or not to initiate biphasic 
insulin aspart, one must take into consideration patient prefer-
ences, compliance, and dietary habits.
Conclusions
In conclusion, the evidence for biphasic insulin aspart sup-
ports its role as a safe, and efﬁ  cacious alternative therapeutic 
modality for achieving glycemic control in patients with 
diabetes. Patients with type 2 diabetes who are failing OHD, 
can be brought to goal with the simple addition of biphasic 
insulin aspart 70/30 once or twice daily. Compared to other 
insulins, biphasic insulin aspart 70/30 more effectively 
reduces post-prandial glucose, which is being increasingly 
recognized as an important component of good glycemic 
management. Biphasic insulin aspart has been shown to be 
as efﬁ  cacious as other insulins in reducing HbA1c. The rate 
of hypoglycemia with biphasic insulin aspart is similar to 
that seen with other insulins. However, there are situations 
when the disadvantages of biphasic insulin aspart outweigh 
its advantages, and alternative treatment regimens may be 
more appropriate.
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